Clinical Exome Sequencing (CES) – TRIO_ONCO with MCC
Advanced Comprehensive Genomic Testing for Oncology & Hereditary Cancer Evaluation
Test Name
Clinical Exome Sequencing (CES) – TRIO_ONCO with MCC
Overview
Clinical Exome Sequencing (CES) – TRIO_ONCO with MCC is an advanced next-generation sequencing (NGS) based genomic test designed to identify clinically relevant genetic variations associated with hereditary cancers, tumor predisposition syndromes, and precision oncology.
This comprehensive assay evaluates coding regions of clinically significant genes and enables simultaneous assessment of:
- Germline mutations
- Somatic variants
- Inherited cancer syndromes
- Rare oncogenic alterations
- Therapy-guiding biomarkers
- Familial segregation analysis through Trio evaluation
The TRIO approach analyzes samples from:
- Patient / Proband
- Biological Mother
- Biological Father
This improves variant interpretation accuracy and supports better clinical decision-making.
MCC (Maternal Cell Contamination) analysis enhances sample quality assessment and improves analytical confidence in specific specimen types.
Technology Platform
- Next Generation Sequencing (NGS)
- Clinical Exome Sequencing Technology
- High-depth coverage sequencing
- Advanced bioinformatics pipeline
- ACMG-guided variant classification
- AI-assisted genomic interpretation
Clinical Applications
Oncology Applications
- Hereditary cancer risk assessment
- Early-onset cancers
- Familial cancer syndromes
- Precision oncology profiling
- Therapy selection guidance
- Prognostic marker identification
- Tumor predisposition evaluation
- Rare cancer gene detection
Commonly Associated Conditions
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Prostate Cancer
- Pancreatic Cancer
- Endometrial Cancer
- Hematological Malignancies
- Pediatric Cancers
- Neuroendocrine Tumors
- Sarcoma Syndromes
Genes & Variant Analysis
The assay evaluates clinically relevant genes associated with:
- DNA repair pathways
- Tumor suppressor genes
- Oncogenes
- Cell-cycle regulation
- Hereditary cancer syndromes
- Pharmacogenomic markers
- Immunotherapy-related biomarkers
Variant types analyzed include:
- Single Nucleotide Variants (SNVs)
- Insertions & Deletions (Indels)
- Copy Number Variations (CNVs)
- Splice-site variants
- Clinically significant exonic alterations
Advantages of TRIO Analysis
- Improved variant interpretation
- Better differentiation of inherited vs de novo variants
- Increased diagnostic yield
- Reduced uncertain findings
- Enhanced genetic counseling support
- Superior family-based genomic analysis
